2024 ICD-10-CM Diagnosis Code M33.20

Polymyositis, organ involvement unspecified

ICD-10-CM Code:
M33.20
ICD-10 Code for:
Polymyositis, organ involvement unspecified
Is Billable?
Yes - Valid for Submission
Chronic Condition Indicator: [1]
Chronic
Code Navigator:

Code Classification

  • Diseases of the musculoskeletal system and connective tissue
    (M00–M99)
    • Systemic connective tissue disorders
      (M30-M36)
      • Dermatopolymyositis
        (M33)

M33.20 is a billable diagnosis code used to specify a medical diagnosis of polymyositis, organ involvement unspecified. The code is valid during the current fiscal year for the submission of HIPAA-covered transactions from October 01, 2023 through September 30, 2024.

Unspecified diagnosis codes like M33.20 are acceptable when clinical information is unknown or not available about a particular condition. Although a more specific code is preferable, unspecified codes should be used when such codes most accurately reflect what is known about a patient's condition. Specific diagnosis codes should not be used if not supported by the patient's medical record.

Approximate Synonyms

The following clinical terms are approximate synonyms or lay terms that might be used to identify the correct diagnosis code:

  • Antisynthetase syndrome
  • Antisynthetase syndrome due to polymyositis
  • Connective tissue disease overlap syndrome
  • Eosinophilic polymyositis
  • Idiopathic inflammatory myopathy
  • Idiopathic polymyositis
  • Juvenile polymyositis
  • Overlap syndrome
  • Polymyositis
  • Polymyositis
  • Polymyositis
  • Polymyositis
  • Polymyositis associated with autoimmune disease
  • Polymyositis overlap syndrome
  • Polymyositis with malignant disease

Clinical Classification

Clinical Information

  • Dermatomyositis

    a subacute or chronic inflammatory disease of muscle and skin, marked by proximal muscle weakness and a characteristic skin rash. the illness occurs with approximately equal frequency in children and adults. the skin lesions usually take the form of a purplish rash (or less often an exfoliative dermatitis) involving the nose, cheeks, forehead, upper trunk, and arms. the disease is associated with a complement mediated intramuscular microangiopathy, leading to loss of capillaries, muscle ischemia, muscle-fiber necrosis, and perifascicular atrophy. the childhood form of this disease tends to evolve into a systemic vasculitis. dermatomyositis may occur in association with malignant neoplasms. (from adams et al., principles of neurology, 6th ed, pp1405-6)
  • Polymyositis

    diseases characterized by inflammation involving multiple muscles. this may occur as an acute or chronic condition associated with medication toxicity (drug toxicity); connective tissue diseases; infections; malignant neoplasms; and other disorders. the term polymyositis is frequently used to refer to a specific clinical entity characterized by subacute or slowly progressing symmetrical weakness primarily affecting the proximal limb and trunk muscles. the illness may occur at any age, but is most frequent in the fourth to sixth decade of life. weakness of pharyngeal and laryngeal muscles, interstitial lung disease, and inflammation of the myocardium may also occur. muscle biopsy reveals widespread destruction of segments of muscle fibers and an inflammatory cellular response. (adams et al., principles of neurology, 6th ed, pp1404-9)
  • Exosome Component 10|Autoantigen PM-SCL|Autoantigen PM/Scl|EC 3.1.13.-|EXOSC10|P100 Polymyositis-Scleroderma Overlap Syndrome-Associated Autoantigen|PM/Scl-100|Polymyositis/Scleroderma Autoantigen 100 kDa|Polymyositis/Scleroderma Autoantigen 2

    exosome component 10 (885 aa, ~101 kda) is encoded by the human exosc10 gene. this protein plays a role in the maturation and degradation of rna.
  • Other Overlap Syndromes|Other overlap syndromes

    evidence of other overlap syndromes not specified elsewhere.
  • Overlap Syndrome

    an autoimmune, connective tissue disorder in which the patient exhibits features from two or more diseases. these typically include systemic sclerosis, dermatomyositis, polymyositis, rheumatoid arthritis, systemic lupus erythematosus, and sjogren syndrome; in pediatrics the respective pediatric entities are encountered.
  • Scleroderma Polymyositis Overlap Syndrome|Scleroderma Polymyositis

    a rare autoimmune disorder in which patients present with overlapping symptoms of systemic scleroderma and polymyositis or dermatomyositis.

Index to Diseases and Injuries References

The following annotation back-references for this diagnosis code are found in the injuries and diseases index. The Index to Diseases and Injuries is an alphabetical listing of medical terms, with each term mapped to one or more ICD-10-CM code(s).

Convert M33.20 to ICD-9-CM

  • ICD-9-CM Code: 710.4 - Polymyositis
    Approximate Flag - The approximate mapping means there is not an exact match between the ICD-10 and ICD-9 codes and the mapped code is not a precise representation of the original code.

Patient Education


Myositis

Myositis means inflammation of the muscles that you use to move your body. An injury, infection, or autoimmune disease can cause it. Two specific kinds are polymyositis and dermatomyositis. Polymyositis causes muscle weakness, usually in the muscles closest to the trunk of your body. Dermatomyositis causes muscle weakness, plus a skin rash.

Other symptoms of myositis may include:

  • Fatigue after walking or standing
  • Tripping or falling
  • Trouble swallowing or breathing

Doctors may use a physical exam, lab tests, imaging tests and a muscle biopsy to diagnose myositis. There is no cure for these diseases, but you can treat the symptoms. Polymyositis and dermatomyositis are first treated with high doses of a corticosteroid. Other options include medications, physical therapy, exercise, heat therapy, assistive devices, and rest.

NIH: National Institute of Neurological Disorders and Stroke


[Learn More in MedlinePlus]

Code History

  • FY 2024 - No Change, effective from 10/1/2023 through 9/30/2024
  • FY 2023 - No Change, effective from 10/1/2022 through 9/30/2023
  • FY 2022 - No Change, effective from 10/1/2021 through 9/30/2022
  • FY 2021 - No Change, effective from 10/1/2020 through 9/30/2021
  • FY 2020 - No Change, effective from 10/1/2019 through 9/30/2020
  • FY 2019 - No Change, effective from 10/1/2018 through 9/30/2019
  • FY 2018 - No Change, effective from 10/1/2017 through 9/30/2018
  • FY 2017 - No Change, effective from 10/1/2016 through 9/30/2017
  • FY 2016 - New Code, effective from 10/1/2015 through 9/30/2016. This was the first year ICD-10-CM was implemented into the HIPAA code set.

Footnotes

[1] Chronic - a chronic condition code indicates a condition lasting 12 months or longer and its effect on the patient based on one or both of the following criteria:

  • The condition results in the need for ongoing intervention with medical products,treatment, services, and special equipment
  • The condition places limitations on self-care, independent living, and social interactions.